Successful ceftolozane/tazobactam treatment of chronic pulmonary infection with pan‐resistant Pseudomonas aeruginosa

Reham Soliman, Sarah Lynch, Emma Meader, Rachel Pike, Jane F. Turton, Robert L.R. Hill, Neil Woodford, David Livermore

Research output: Contribution to journalArticlepeer-review

10 Downloads (Pure)


The treatment of chronic Pseudomonas aeruginosa infections is challenging, with resistance and antibiogram diversity accumulating during successive therapies. Some isolates are resistant to all licensed agents, creating treatment problems and an urgent need for new therapies. Among antibiotics in advanced development, ceftolozane/tazobactam has potent in vitro antipseudomonal activity, with low MICs even for strains with AmpC β‐lactamase‐, impermeability‐ and efflux‐mediated resistance to other β‐lactams.
Original languageEnglish
JournalJMM Case Reports
Early online date1 Apr 2015
Publication statusPublished - 2015


  • Pseudomonas
  • pan‐resistance
  • aeruginosa
  • ceftolozane‐tazobactam
  • bronchiectasis

Cite this